Key Highlights

  • REPL shares are trading up 101.66% today to $10.91, up from a prior close of $5.41.
  • An FDA advisory committee voted 10-3 that efficacy results from the IGNYTE study for RP1 are evaluable and clinically meaningful.
  • The vote is non-binding, but increases the likelihood of approval after RP1 was previously rejected twice by the FDA.
  • The FDA's target action date for the resubmitted Biologics License Application is August 2, 2026.

Advisory Panel Backs Twice-Rejected Melanoma Therapy

Replimune Group, Inc. (NASDAQ:REPL) shares are more than doubling today after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy results from the company's IGNYTE study for RP1 (vusolimogene oderparepvec) are evaluable and clinically meaningful. Replimune, headquartered in Woburn, Massachusetts and founded in 2015, is a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies based on a proprietary herpes simplex virus platform.

The committee's favorable vote follows two prior rejections of RP1 by the FDA, most recently in April, when regulators requested additional evidence from a more rigorously controlled study. FDA staff had raised efficacy concerns ahead of the meeting, arguing the single-arm IGNYTE trial's lack of a comparator group limited the ability to isolate RP1's independent contribution to outcomes, a concern that had sent shares down roughly 30% earlier in the week.

Non-Binding Vote and Path to FDA Decision

Replimune carries a market capitalization of approximately $916.05 million, with shares trading within a 52-week range of $1.50 to $12.50. The stock posted a trailing loss of $3.38 per share and does not currently report a trailing price-to-earnings multiple.

RP1 is being developed in combination with Bristol Myers Squibb's (NYSE:BMY) nivolumab, marketed as Opdivo, for patients with advanced melanoma who have progressed on prior anti-PD-1 therapy such as Merck's (NYSE:MRK) Keytruda. Replimune reported an objective response rate of approximately 33.6% and a median duration of response of 24.8 months among IGNYTE trial participants treated with RP1 plus nivolumab.

While advisory committee recommendations are not binding on the FDA, the agency typically gives significant weight to their conclusions, and Thursday's vote raises the probability that RP1 will receive approval ahead of the FDA's August 2 target action date under the Class 1 resubmission review. More than 30 patients and physicians spoke in favor of the therapy during the meeting's public comment period, underscoring the limited treatment options currently available to this patient population.

Conclusion

Replimune's dramatic rally reflects genuine regulatory progress after two prior rejections, with the advisory committee's favorable vote materially improving the odds of approval even though the FDA retains full discretion over its final decision. With the agency's August 2 action date fast approaching, investors will be watching closely for confirmation that regulators align with the panel's assessment of the IGNYTE data.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.